STERO Biotechs - The Team

shadow

Mr. David Bassa - CEO

Mr. David Bassa is an experienced and prolific entrepreneur.
David owns a number of pharmaceutical and drug development companies. He led the first Cannabis pharma ‘Exit’ in Israel, founded & acted as CEO of Talent Biotech (until its sale), and other ventures. He’s the main shareholder of 5 biotech or hi-tech startups. David has received two excellence awards from the president of Israel.

shadow

Mr. Ofer Alshech - CFO

An experienced CFO in public and private, multi-million and start-up companies with strong organizational skills and extensive experience in financial management. Ofer has vast experience in fundraising from private equity, private investors and leading IPOs. He also has a deep understanding of business drivers, risks and opportunities. For the past 8 years Ofer served as CFO at “Reshet 13”.

shadow

Mr. Guy Defrin - COO

As an experienced COO Guy also Serves as the active COO of CannaLean Biotechs, CannaMore Biotechs, the biotech startup accelerator BioSeedXL and other companies in the pharmaceutical and Cannabis fields.
He holds a B.Sc. in Biology and Life Science at Tel Aviv University with a major in biochemistry research.

shadow

Dr. Sari Prutchi Sagiv - CSO

Dr Sagiv brings over 20 years of proven management experience in the fields of preclinical and clinical development, regulatory and intellectual property from the bio-tech industries. Has managed R&D in various cannabis companies including BOL, Kalytera and CannaMore.
Dr. Sagiv also manages the pharma and diagnostics department at Mor Research Applications, the Technology Transfer unit of ‘CLALIT’ Health Services.
Dr. Sagiv holds a MSc in Genetics, a PhD in Immunology and studied for an MBA at Tel Aviv University.

shadow

Dr. Moshe Yeshurun, MD – CTO

Specialist in Internal Medicine, Hematology and Bone Marrow Transplantation. Director of the Bone Marrow Transplantation Unit at Rabin Medical Center, Israel. The inventor of a CBD based drug and IP for treatment of GvHD, sold to publicly traded Kalytera Therapeutics (TSXV: KALY).

shadow

Dr. Naftali Timna, MD - IBD Medical Director

Deputy Director and Specialist in Gastroenterology and liver disease at Meir Hospital and CLALIT. She has extensive experience in both the IBD and Cannabis fields, including research and clinical trials with the collaboration of Tikun Olam.

shadow

Prof. Ronit Confino, MD - Urticaria Medical Director

Head of drug allergy service at the Allergy and Clinical Immunology Unit, Meir Medical Center.
Head of Allergy and Clinical Immunology Unit, Meir Medical Center.